DK2968205T3 - Produkt og fremgangsmåde til behandling af diarré - Google Patents

Produkt og fremgangsmåde til behandling af diarré

Info

Publication number
DK2968205T3
DK2968205T3 DK14722445.5T DK14722445T DK2968205T3 DK 2968205 T3 DK2968205 T3 DK 2968205T3 DK 14722445 T DK14722445 T DK 14722445T DK 2968205 T3 DK2968205 T3 DK 2968205T3
Authority
DK
Denmark
Prior art keywords
diary
treatment
product
Prior art date
Application number
DK14722445.5T
Other languages
Danish (da)
English (en)
Inventor
Ii Reed B Hogan
Original Assignee
Maregade Rx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maregade Rx Llc filed Critical Maregade Rx Llc
Application granted granted Critical
Publication of DK2968205T3 publication Critical patent/DK2968205T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK14722445.5T 2013-03-14 2014-03-14 Produkt og fremgangsmåde til behandling af diarré DK2968205T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361782608P 2013-03-14 2013-03-14
PCT/US2014/027323 WO2014152420A2 (en) 2013-03-14 2014-03-14 Product and method for treating diarrhea

Publications (1)

Publication Number Publication Date
DK2968205T3 true DK2968205T3 (da) 2017-11-27

Family

ID=50680150

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14722445.5T DK2968205T3 (da) 2013-03-14 2014-03-14 Produkt og fremgangsmåde til behandling af diarré

Country Status (20)

Country Link
US (4) US9717726B2 (enExample)
EP (3) EP3269364B1 (enExample)
JP (4) JP6313417B2 (enExample)
KR (4) KR20180088514A (enExample)
CN (2) CN108939076A (enExample)
AU (3) AU2014239878B2 (enExample)
BR (2) BR122017004716A2 (enExample)
CA (1) CA2906005C (enExample)
DK (1) DK2968205T3 (enExample)
ES (2) ES2655505T3 (enExample)
HK (1) HK1247557B (enExample)
HU (1) HUE035201T2 (enExample)
IL (3) IL273377B2 (enExample)
MX (2) MX366329B (enExample)
MY (1) MY175326A (enExample)
PL (1) PL2968205T3 (enExample)
PT (1) PT2968205T (enExample)
RU (1) RU2015143475A (enExample)
WO (1) WO2014152420A2 (enExample)
ZA (1) ZA201708539B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717726B2 (en) 2013-03-14 2017-08-01 Maregade Rx, LLC Product and method for treating diarrhea
US20150132410A1 (en) * 2013-11-14 2015-05-14 Michael M. Jacobs Compositions and methods for the prevention and treatment of alcohol-induced hangover syndrome
US20180185356A1 (en) * 2016-12-23 2018-07-05 Maregade Rx, LLC Low dose product and method for treating diarrhea
IT201900012645A1 (it) * 2019-07-23 2021-01-23 Eros Zanotti Una composizione farmaceutica per l'uso nel trattamento delle chinetosi
CN112616320B (zh) * 2019-08-05 2024-04-05 株式会社日立高新技术 等离子处理装置
CN115515435A (zh) * 2020-02-11 2022-12-23 沃尔夫森医疗中心 有效治疗溃疡性结肠炎的方法
CN117280446A (zh) 2021-08-23 2023-12-22 株式会社日立高新技术 等离子处理装置以及等离子处理方法
WO2023049205A1 (en) 2021-09-22 2023-03-30 Hista Rx Llc Compositions and methods for treating and preventing interstitial cystitis

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204118A (en) 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
US5096894A (en) * 1990-04-03 1992-03-17 Bristol-Myers Squibb Company Rice dextrin oral rehydration solution
AU7255094A (en) 1993-07-06 1995-02-06 Mcneil-Ppc, Inc. H2 antagonist-antihistamine combinations
US6264984B1 (en) * 1999-12-06 2001-07-24 Bristol-Myers Squibb Company Effervescent histamine H2 antagonist composition
US6656492B2 (en) * 2000-06-30 2003-12-02 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
CA2430292A1 (en) 2000-11-30 2002-06-06 The Bio Balance Corp. Preparation of compositions comprising bacterial strains and volatile plant extracts and therapeutic and industrial applications thereof
WO2003044023A1 (en) * 2001-11-23 2003-05-30 Janssen Pharmaceutica N.V. The use of anti-histaminics for acute reduction of elevated intracranial pressure
SE528789C2 (sv) 2004-09-10 2007-02-13 Sandvik Intellectual Property PVD-belagt skär av hårdmetall samt sätt att tillverka detta
US20070077300A1 (en) * 2005-09-30 2007-04-05 Wynn David W Oral compositions containing a salivation inducing agent
US20090312358A1 (en) 2006-03-22 2009-12-17 Trustees Of Boston University Method for management of diarrhea
US8207188B2 (en) 2006-04-07 2012-06-26 Michalis Nicolaou Treatment of diseases modulated by a H4 receptor agonist
US8207292B2 (en) 2007-02-12 2012-06-26 Michalis Nicolaou Treatment of COPD, gastro-esophageal reflux disease (GERD), food allergies and other gastrointestinal conditions and disorders ameliorated by proper histamine management using a combination of histidine decarboxylase inhibitors, LRA drugs, anti-H1 and/or anti-H2 drugs
US20070254050A1 (en) * 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
US20090042972A1 (en) * 2006-05-19 2009-02-12 Somaxon Pharmaceuticals, Inc. Methods of using low-dose doxepin for the improvement of sleep
CA2721133C (en) * 2007-04-13 2018-11-06 Somaxon Pharmaceuticals, Inc. Low-dose doxepin formulations and methods of making and using the same
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
EP3415627A1 (en) 2012-11-13 2018-12-19 Codiak BioSciences, Inc. Delivery of therapeutic agent
US9717726B2 (en) 2013-03-14 2017-08-01 Maregade Rx, LLC Product and method for treating diarrhea
US20180185356A1 (en) 2016-12-23 2018-07-05 Maregade Rx, LLC Low dose product and method for treating diarrhea

Also Published As

Publication number Publication date
HK1247557B (en) 2020-07-03
KR20150139535A (ko) 2015-12-11
IL273377B1 (en) 2023-06-01
IL241372A0 (en) 2015-11-30
JP6790140B2 (ja) 2020-11-25
US20190038619A1 (en) 2019-02-07
KR101884506B1 (ko) 2018-08-01
HK1213205A1 (en) 2016-06-30
US11058681B2 (en) 2021-07-13
WO2014152420A3 (en) 2014-11-20
IL256300B (en) 2020-04-30
HUE035201T2 (hu) 2018-05-02
ZA201708539B (en) 2019-05-29
AU2019201412A1 (en) 2019-03-21
JP2021046400A (ja) 2021-03-25
WO2014152420A2 (en) 2014-09-25
US20140275116A1 (en) 2014-09-18
JP2018135340A (ja) 2018-08-30
BR122017004716A2 (pt) 2019-07-30
KR20180088514A (ko) 2018-08-03
EP3269364A1 (en) 2018-01-17
US10034875B2 (en) 2018-07-31
CA2906005A1 (en) 2014-09-25
EP3269364B1 (en) 2019-05-29
IL241372B (en) 2018-06-28
RU2015143475A (ru) 2017-04-20
PT2968205T (pt) 2018-01-05
BR112015022513A2 (pt) 2017-07-18
KR102449977B1 (ko) 2022-09-30
JP2016513692A (ja) 2016-05-16
EP3581205A2 (en) 2019-12-18
ES2655505T3 (es) 2018-02-20
EP2968205A2 (en) 2016-01-20
US20170049770A1 (en) 2017-02-23
MX366329B (es) 2019-07-05
US20220047583A1 (en) 2022-02-17
AU2014239878A1 (en) 2015-10-15
MX2015011885A (es) 2016-05-16
AU2014239878B2 (en) 2017-08-24
US9717726B2 (en) 2017-08-01
CN105324112A (zh) 2016-02-10
ES2743604T3 (es) 2020-02-20
JP2019089796A (ja) 2019-06-13
AU2017251701B2 (en) 2019-03-14
IL256300A (en) 2018-02-28
JP6473254B2 (ja) 2019-02-20
EP3581205A3 (en) 2020-03-25
JP6313417B2 (ja) 2018-04-18
IL273377B2 (en) 2023-10-01
IL273377A (en) 2020-05-31
KR20210021606A (ko) 2021-02-26
MX350814B (es) 2017-09-21
CN108939076A (zh) 2018-12-07
CN105324112B (zh) 2018-08-17
PL2968205T3 (pl) 2018-03-30
AU2017251701A1 (en) 2017-11-09
CA2906005C (en) 2021-12-28
KR20200100211A (ko) 2020-08-25
MY175326A (en) 2020-06-19
EP2968205B1 (en) 2017-10-11

Similar Documents

Publication Publication Date Title
DK3178849T3 (da) Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer
DK3353210T3 (da) Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse
DK3295951T3 (da) Anti-pvrig-antistoffer og fremgangsmåder for anvendelse
DK3039146T3 (da) Produkter og fremgangsmåder til behandling af amyotrofisk lateral sklerose
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3303386T3 (da) Anti-Tau-antistoffer og fremgangsmåder til anvendlelse
DK3215532T3 (da) Anti-TIM3-antistoffer og fremgangsmåder til anvendelse
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
DK3230319T3 (da) Anti-PD-1-antistoffer og fremgangsmåder til anvendelse deraf
LT3981792T (lt) Pd-1 surišančios molekulės ir jų panaudojimo būdai
DK3218005T5 (da) Glycan-interagerende forbindelser og anvendelsesfremgangsmåder
DK3126394T3 (da) Anti-OX40-antistoffer og fremgangsmåder til anvendelse
DK4000608T3 (da) Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf
DK3148579T3 (da) Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
DK3009021T3 (da) Handske og fremgangsmåde til fremstilling deraf
DK3160966T3 (da) Mnk-inhibitorer og fremgangsmåder forbundet dermed
DK3019200T3 (da) Oligonukleotid-ligand-konjugater og fremgangsmåde til fremstiling deraf
DK3215147T3 (da) Neurodæmpende norketamin-forbindelser og fremgangsmåder
DK3394065T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf
DK3586645T3 (da) System og fremgangsmåde til fremstilling af et ekstruderet proteinprodukt
DK2914627T3 (da) Anti-cd40-antistoffer og fremgangsmåder til anvendelse
DK3003699T3 (da) Fodtøjsgenstand og fremgangsmåden til dannelse af genstanden
DK2882496T3 (da) Behandling og diagnosticering af melanom
DK3086807T3 (da) Antistoffer og fremgangsmåder til anvendelse
DK3089971T3 (da) Forbindelser og fremgangsmåder til anvendelse